A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem raka jelita grubego w zaawansowanym stadium lub z przerzutami
- •Poprzednie leczenie fluoropirymidyną, oksaliplatyną, irynotekanem i innymi standardowymi lekami
- •Choroba się pogorszyła lub pacjent nie tolerował poprzedniego leczenia
- •Zdolność połykania tabletek i wchłaniania leków doustnych
- •Wystarczające funkcje wątroby, nerek i szpiku kostnego potwierdzone badaniami krwi
- •Możliwość uczestniczenia we wszystkich wizytach badania przez cały czas trwania
- •Wyraźna i wymieralna zmiana nowotworu widoczna w badaniach obrazowych
✗ Disqualifies
- •Pacjenci, którzy wcześniej pogorszyli się na irynotekanem i oksaliplatyną nie powinni ponownie otrzymywać tych leków przed wpisem do badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (13)
Yale University
New Haven, United States
Mount Sinai Cancer Research Program
Miami Beach, United States
Orlando Health Cancer Institute
Orlando, United States
Rutgers Cancer Institute
New Brunswick, United States
NYU Langone Health
New York, United States
UPenn Lancaster-Ann B. Barshinger Cancer Institute
Lancaster, United States
Thomas Jefferson University - Sidney Kimmel Comprehensive Cancer Center
Philadelphia, United States
UPMC / University of Pittsburgh Medical Center
Pittsburgh, United States
Medical University of South Carolina / MUSC
Charleston, United States
Vanderbilt University Medical Center
Nashville, United States
Mays Cancer Center at University of Texas Health at San Antonio
San Antonio, United States
Inova Schar Cancer
Fairfax, United States
Swedish Cancer Institute
Seattle, United States
Trial contact
Soumaya Chappidi
Julee Hartwell
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.